Abstract
Background
O6-methylguanine-DNA-methyl transferase (MGMT), a DNA repair gene, is a key enzyme for predicting the response to both radiotherapy and temozolomide in glioma patients. Data on the MGMT promoter methylation status in relation to the time to develop intracranial new metastasis or local relapse at the surgical site after brain surgery followed by radiotherapy is limited in non-smallcell lung cancer (NSCLC) patients with a single brain metastasis.
Methods
All 55 patients included in this analysis were NSCLC with a single brain metastasis and had undergone brain surgery followed by radiotherapy. Genomic DNA was extracted from the brain tumour. The DNA was treated with bisulphate and a methylation-specific polymerase chain reaction was performed. Survival was compared by the status of promoter region of MGMT.
Results
The time to develop intracranial new metastases or local relapse at the surgical site after treatment in patients with methylation of the MGMT promoter region was 4.0 months (N=5), while that of the patients without methylation of the MGMT promoter region was 11.5 months (N=50) (p=0.37).
Conclusions
NSCLC patients with brain metastasis treated by brain surgery followed by radiotherapy may have a higher chance of relapse when the tumour has methylation of the MGMT promoter region.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tano K, Shiota S, Collier J et al (1990) Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Natl Acad Sci U S A 87: 686–690
Citron M, Graver M, Schoenhaus M et al (1992) Detection of messenger RNA from O6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues. J Natl Cancer Inst 84:337–340
Costello JF, Futscher BW, Tano K et al (1994) Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 269:17228–17237
Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388–2399
Dolan ME, Pegg AE (1997) O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3:837–847
Jaeckle KA, Eyre HJ, Townsend JJ et al (1998) Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16:3310–3315
Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefi t from temozolomide in glioblastoma. N Engl J Med 352:997–1003
Rivera AL, Pelloski CE, Gilbert MR et al (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116–121
Margison GP, Butler J, Hoey B (1985) O6-Methylguanine methyltransferase activity is increased in rat tissues by ionising radiation. Carcinogenesis 6:1699–702
Chan CL, Wu Z, Eastman A, Bresnick E (1992) Irradiation-induced expression of O6-methylguanine-DNA methyltransferase in mammalian cells. Cancer Res 52:1804–1809
von Hofe E, Kennedy AR (1988) In vitro induction of O6-methylguanine-DNA methyltransferase in C3H/10T1/2 cells by X-rays is inhibited by nitrogen. Carcinogenesis 9:679–681
Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354
Palmisano WA, Divine KK, Saccomanno G et al (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954–5958
Wu PF, Kuo KT, Kuo LT et al (2010) O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer 68:484–490
Bae SI, Lee HS, Kim SH, Kim WH (2002) Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers. Br J Cancer 86:1888–1892
Esteller M, Gaidano G, Goodman SN et al (2002) Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94:26–32
Baumann S, Keller G, Puhringer F et al (2006) The prognostic impact of O6-methylguanine-DNA methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer 119:264–268
Cayre A, Penault-Llorca F, De Latour M et al (2002) O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. Int J Oncol 21:1125–1131
Park TJ, Han SU, Cho YK et al (2001) Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated signifi cantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 92:2760–2768
Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hashimoto, K., Narita, Y., Matsushita, Y. et al. Methylation status of O6-methylguanine-DNA-methyl transferase promoter region in non-small-cell lung cancer patients with brain metastasis. Clin Transl Oncol 14, 31–35 (2012). https://doi.org/10.1007/s12094-012-0758-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0758-6